SABCS 2021 Updates in Key Clinical Trials for Breast Cancer
Patrick Neven MD, PhD; Sara A. Hurvitz, MD; Kevin Kalinsky, MD, MS; and Aditya Bardia, MD, MPH, share insight on updates in key clinical trials and novel therapies in breast cancer presented at SABCS 2021.
Data from the following clinical trials are discussed:
- GS2-05 oral presentation: Randomized comparision of adjuvant aromatase inhibitor exemestane + ovarian function suppression (OFS) vs tamoxifen + OFS in premenopausal women with hormone receptor-positive early breast cancer: update of the TEXT and SOFT trials
- GS3-00: First results from a phase 3 randomized clinical trail of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and HER2-negative breast cancer with recurrence score < 25: SWOG S1007 (RxPONDER)
- GS1-08: CCTGMA.32, a phase 3 randomized double-blind placebo-controlled adjuvant trial of metformin vs placebo in early breast cancer: Results of the primary efficacy analysis (NCT0110143)
- GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2 breast cancer: Results from the phase 1 TROPION-PanTumor01 study
Related Videos
Related Content
